The estimated Net Worth of Jeremy G Chadwick is at least 2.07 百万$ dollars as of 23 May 2024. Jeremy Chadwick owns over 2,575 units of Kymera Therapeutics stock worth over 1,978,073$ and over the last 2 years Jeremy sold KYMR stock worth over 90,099$.
Jeremy has made over 1 trades of the Kymera Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently Jeremy sold 2,575 units of KYMR stock worth 90,099$ on 23 May 2024.
The largest trade Jeremy's ever made was selling 2,575 units of Kymera Therapeutics stock on 23 May 2024 worth over 90,099$. On average, Jeremy trades about 858 units every 0 days since 2023. As of 23 May 2024 Jeremy still owns at least 44,183 units of Kymera Therapeutics stock.
You can see the complete history of Jeremy Chadwick stock trades at the bottom of the page.
Jeremy's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Kymera Therapeutics have traded over 179,227,903$ worth of Kymera Therapeutics stock and bought 2,497,406 units worth 70,844,455$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Bros. Advisors Lp667, L.P.B...、Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of 3,989,455$. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth 51,700$.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: